ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/067/SRR16132067/SRR16132067_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/056/SRR16157056/SRR16157056_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/054/SRR16157054/SRR16157054_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/053/SRR16157053/SRR16157053_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/053/SRR16157053/SRR16157053_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/055/SRR16157055/SRR16157055_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/067/SRR16132067/SRR16132067_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/056/SRR16157056/SRR16157056_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/066/SRR16132066/SRR16132066_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/066/SRR16132066/SRR16132066_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/055/SRR16157055/SRR16157055_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR161/054/SRR16157054/SRR16157054_1.fastq.gzprimaryOK200GenomicsThe first affiliated hospital of USTChttps://www.ebi.ac.uk/ena/browser/view/PRJNA767433xref:EuropePMC:PMC8565356Evidence suggests that histone modification disorders are involved in leukemia pathogenesis. We previously reported that LukS-PV, a component of Panton-Valentine leukocidin (PVL), has anti-leukemia activities that can induce differentiation, increase apoptosis, and inhibit proliferation of acute myeloid leukemia (AML) cells. Furthermore, LukS-PV inhibited hepatoma progression by regulating histone deacetylation, speculating that LukS-PV may exert anti-leukemia activity by targeting histone modification regulators. In this study, the results showed that LukS-PV induced apoptosis by downregulating the methyltransferase SET8 and its target histone H4 monomethylated at Lys 20 (H4K20me1)ENAfalseLukS-PV induces AML cell apoptosis by targeting SET8.2023-05-192021-10-18PRJNA767433